4558.T
CHUKYO IYAKUHIN CO.,LTD.
スタンダード · 医薬品 · 医薬品 · JP
JPY 202.00
+0.00%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 6.6B | 6.6B | 6.3B | 6.1B | 5.7B |
| Cost of Revenue | 738.2M | — | 2.7B | 2.4B | 2.0B |
| Gross Profit | 983.9M | 3.7B | 3.6B | 3.7B | 3.7B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 891.5M | 3.6B | 3.5B | 3.6B | 3.6B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 891.5M | 3.6B | 3.5B | 3.6B | 3.6B |
| Cost and Expenses | 6.4B | 6.4B | 6.2B | 6.0B | 5.6B |
| Operating Income (EBIT) | 127.0M | 127.0M | 106.0M | 128.0M | 59.0M |
| Non-Operating | |||||
| Interest Income | 37.0K | 1.2M | 404.0K | 21.0K | 23.0K |
| Interest Expense | 3.2M | 13.9M | 8.8M | 4.0M | 4.4M |
| Net Interest Income | (3.2M) | (12.7M) | (8.4M) | (3.9M) | (4.3M) |
| Other Non-Op Income/Expense | 3.9M | 12.2M | 11.5M | 19.5M | 20.0M |
| Non-Operating Income (excl Interest) | 7.1M | 25.0M | 19.9M | 23.4M | 24.3M |
| EBT (Pre-Tax Income) | 100.4M | 118.8M | 125.8M | 20.3M | 77.4M |
| Income Tax Expense | 33.2M | 35.2M | 80.6M | 47.6M | 62.9M |
| Bottom Line | |||||
| Net Income | 83.0M | 83.0M | 45.0M | (27.0M) | 14.0M |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 83.0M | 83.0M | 45.0M | (27.0M) | 14.0M |
| Per Share | |||||
| Basic EPS | ¥8 | ¥8 | ¥4 | (¥3) | ¥1 |
| Diluted EPS | ¥8 | ¥8 | — | — | — |
| Revenue Per Share | ¥616 | ¥616 | ¥592 | ¥575 | ¥535 |
| Shares | |||||
| Basic Shares Outstanding | 10.7M | 10.7M | 10.7M | 10.6M | 10.6M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | — | 173.5M | 161.8M | 182.6M | 113.3M |
| D&A | — | 46.5M | 55.9M | 54.6M | 54.3M |
| EBIT | 127.0M | 127.0M | 106.0M | 128.0M | 59.0M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026